Prepared by R.R. Donnelley Financial -- FORM 8-K

0000950168-02-002893.txt : 20021003 0000950168-02-002893.hdr.sgml : 20021003 20021003141743 ACCESSION NUMBER: 0000950168-02-002893 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20021003 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20021003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23265 FILM NUMBER: 02780827 BUSINESS ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 9198621000 MAIL ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 8-K 1 d8k.htm FORM 8-K Prepared by R.R. Donnelley Financial -- FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 3, 2002

SALIX PHARMACEUTICALS, LTD.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

000-23265		94-3267443
(Commission file Number)		(IRS Employer ID Number)

8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615

(Address of principal executive offices) (Zip Code)

(919) 862-1000

Registrant’s telephone number, including area code

Item 5. Other Events and Regulation FD Disclosure

Salix Pharmaceuticals, Ltd. issued a press release on October 3, 2002, announcing that it will present at the UBS Warburg Global Life Sciences Conference on Thursday, October 10 at 1:30 p.m. EDT. A copy of this press release is attached as an exhibit.

Item 7. Financial Statements and Exhibits

99.1 Press Release dated October 3, 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SALIX PHARMACEUTICALS, LTD.

Date: October 3, 2002	By:	/s/ Adam C. Derbyshire
		Adam C. Derbyshire
		Vice President and Chief Financial Officer

EX-99.1 3 dex991.htm PRESS RELEASE Prepared by R.R. Donnelley Financial -- PRESS RELEASE

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:

Adam C. Derbyshire

Mike Freeman

Vice President and

Director, Investor Relations and

Chief Financial Officer

Corporate Communications

919-862-1000

SALIX PHARMACEUTICALS TO PRESENT AT

UBS WARBURG GLOBAL LIFE SCIENCES

CONFERENCE

RALEIGH, NC, October 3, 2002—Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Company will present at the UBS Warburg Global Life Sciences Conference on Thursday, October 10 at 1:30 p.m. EDT.

Interested parties can access a live audio web cast of the presentation at http://www.ubswarburg.com. A replay of the presentation will be available beginning at 4:30 p.m., Thursday, October 10, and will be available through Thursday, October 17.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs; complete the required development and regulatory submission of these products; and market them through the Company’s 60-member gastroenterology specialty sales force. Salix’s first marketed product is COLAZAL^® (balsalazide disodium) Capsules 750 mg, an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis. The Company launched the product in the U.S. through its specialty sales force in January 2001. COLAZAL was well tolerated in clinical studies. In clinical trials, patients reported the following adverse events most frequently: headache (8%); abdominal pain (6%); diarrhea (5%); nausea (5%); vomiting (4%); respiratory infection (4%); and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to placebo. Salix’s next product candidate is rifaximin, currently in development for the potential treatment of infections of the lower gastrointestinal tract. The

Company submitted an NDA for rifaximin for the treatment of travelers’ diarrhea to the FDA on December 26, 2001. Salix trades on the Nasdaq National Market under the ticker symbol “SLXP.”

For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com.

###

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks of regulatory review and clinical trials, the need to acquire additional products and management of rapid growth. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission.